Medtronic and IBM Watson recently partnered to roll out a new artificial intelligence (AI) app for diabetes management. The app, Sugar.IQ, is currently available for consumers who are using Guardian Connect, Medtronic’s continuous glucose monitoring system.
Specifically, Sugar.IQ utilizes AI and analytics to analyze the impact different foods, daily routines, and insulin dosages have on glucose levels. The two organizations anticipate that the app will help to equip individuals with diabetes with the guidance they need to best manage their glucose levels. According to research, Sugar.IQ users spent 36 more minutes per day at healthy glucose ranges.
IBM is an American multinational technology company headquartered in Armonk, New York, with operations in over 170 countries. Watson is a question answering computer system capable of answering questions posted in natural language, developed in IBM’s DeepQA project. Medtronic, Inc. manufactures and sells device-based medical therapies.
This was reported by Becker’s Health IT & CIO Report on June 26, 2018.
Contact Information: Medtronic, 710 Medtronic Parkway, Minneapolis, Minnsesota 55432; (763) 514-4000; www.medtronic.com
Contact Information: IBM Corporation, 1 New Orchard Road, Armonk, New York 10504; (914) 499-1900; Website: www.ibm.com
